A study of a drug combo for relapsed or refractory AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your AML must have either not responded to at least one round of intensive chemo or come back after a remission.
- You must be generally up and about (able to care for yourself, up and about more than half of waking hours).
- Your organs (like liver and kidneys) must work well enough, as checked by your doctor.
- If you are a woman who could become pregnant, you must use effective birth control during the study and for 4 months after. Men must do the same.
- You must not have had a stem cell transplant in the last 3 months or certain chemo regimens before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with acute myeloid leukemia (AML) that has come back or hasn't responded to treatment, including those who have previously taken venetoclax. The goal is to see if this combo can help control the leukemia.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests whether adding a drug called venetoclax to the usual chemotherapy (CLAG) helps people whose acute myeloid leukemia (AML) has come back or not responded to treatment. It aims to see if the combination improves outcomes compared to chemotherapy alone.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.